Skip to Main content Skip to Navigation
Journal articles

Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage

Abstract : COPA (coatomer subunit α) syndrome is a newly recognised cause of interstitial lung disease in children and adults, frequently associated with arthritis and renal dysfunction. We report a 11-year-old girl with disease limited to major pulmonary haemosiderosis manifesting at the age of 2 years, due to a heterozygous p.(Arg233His) mutation in COPA Her interferon (IFN) signature was elevated (10.312 and 12.429, healthy <2.466), as was the level of serum IFNα (211 fg/mL, healthy <10 fg/mL). STAT1 phosphorylation in T lymphocytes and monocytes was increased as compared with healthy controls. Based on these results she was treated with the JAK1/2 inhibitor ruxolitinib, which resulted in reduction in IFN signalling and appeared to be associated with partial though incomplete decrease in the severity of her pulmonary disease. Patients with alveolar haemorrhage of unknown origin should be considered for COPA screening. Functional tests can help to personalise patient therapy.
Document type :
Journal articles
Complete list of metadatas

https://hal-pasteur.archives-ouvertes.fr/pasteur-02376257
Contributor : Marie-Christine Vougny <>
Submitted on : Friday, November 22, 2019 - 2:44:26 PM
Last modification on : Tuesday, September 1, 2020 - 3:21:46 AM

Links full text

Identifiers

Citation

Marie-Louise Frémond, Marie Legendre, Michael Fayon, Annick Clement, Emilie Filhol-Blin, et al.. Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage. Thorax, BMJ Publishing Group, 2019, pp.thoraxjnl-2019-213892. ⟨10.1136/thoraxjnl-2019-213892⟩. ⟨pasteur-02376257⟩

Share

Metrics

Record views

315